28 pág.


DisciplinaClínica e Tratamento das Doenças Prevalentes56 materiais2.631 seguidores
Pré-visualização24 páginas
resistance syndrome. The Oslo Diet and Exercise Study: a
randomized trial. Diabetes Care, v. 20, p. 26\u201331, 1997.
48. Houmard JA, Tanner CJ, Slentz CA et al. The effect of the volume and intensity of
exercise training on insulin sensitivity. J Appl Physiol, v. 96, p. 101\u2013106, 2004.
49. Pan X, Li G, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people
with impaired glucose tolerance. The Da Qing IGT Diabetes Study. Diabetes Care,
v. 20, p. 537\u2013544, 1997.
50. Bacon SL, Sherwood A, Hinderliter A, Blumenthal JA. Effects of exercise, diet and
weight loss on high blood pressure. Sports Med, v. 34, p. 307\u2013316, 2004.
51. Hagberg JM, Park JJ, Brown MD. The role of exercise training in the treatment of
hypertension: an update. Sports Med, v. 30, p. 193\u2013206, 2000.
52. Carrol S, Dudfield M. What is the relationship between exercise and metabolic
abnormalities? A review of the metabolic syndrome. Sports Med, v. 34, p. 371\u2013
418, 2004.
53. Weinstock RS, Dai H, Wadden T. Diet and exercise in the treatment of obesity. Ef-
fects of three interventions on insulin resistance. Arch Int Med, v. 158, p. 2477\u2013
2483, 1998.
54. National Institute of Health. National Heart, Lung and Blood Institute. North Ame-
rican Association for the Study of Obesity. The practical guide-identification, eva-
luation and treatment of overweight and obesity in adults. NIH publication number
00\u20134084. 2000.
55. Hornstra G, Barth CA, Galli C, Mensink RP, Mutanen M, Riemersma RA et al. Func-
tional foods science and the cardiovascular system. Br J Nutr, v. 80, p. S113\u2013
S146, 1998.
56. Ard JD, Grambow SC, Liu D, Slentz CA, Kraus WE, Svetkey L. The effect of the PRE-
MIER interventions on insulin sensitivity. Diabetes Care, v. 27, p. 340\u2013347, 2004.
57. McKeown NM, Meigs JB, Liu S, Saltzmann E, Wilson PW, Jacques PF. Carbohy-
drate nutrition, insulin resistance, and the prevalence of the metabolic syndrome
in the Framingham Offspring Cohort. Diabetes Care, v. 27, p. 538\u2013546, 2004.
58. McKeown NM, Meigs JB, Liu S, Wilson PW, Jacques PF. Whole-grain intake is
favorably associated with metabolic risk factors for type 2 diabetes and cardio-
vascular disease in the Framingham Offspring Study. Am J Clin Nutr, v. 76, p. 390\u2013
398, 2002.
59. U.S. Department of Agriculture and U.S. Department of Health and Human Serv-
ices: Nutrition and Your Health: Dietary Guidelines for Americans. 5th ed. Home and
Garden Bulletin nº 232. Washington, DC: U.S Department of Agriculture, 2000.
60. Riccardi G, Rivellese AA. Effects of dietary fiber and carbohydrate on glucose and lipo-
protein metabolism in diabetic patients. Diabetes Care, v. 14, p. 1115\u20131125, 1991.
61. Frost G, Keogh B, Smith D, Akinsanya K, Leeds A. The effect of low glycemic car-
bohydrate on insulin and glucose response in vivo and in vitro in patients with co-
ronary heart disease. Metabolism, v. 45, p. 669\u2013672, 1996.
62. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome \u2013 the opti-
mal diet. Br J Nutr, v. 83, Suppl 1, p. S143\u2013S148, 2000.
63. Kasim-Karakas SE, Ulmario RU, Mueller WM, Peerson J. Changes in plasma lipo-
proteins during low-fat, high-carbohydrate diets: effects of energy intake. Am J Clin
Nutr, v. 71, p. 1439\u20131447, 2000.
64. Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: a mecha-
nism to improve energy balance and insulin resistance. Br J Nutr, v. 83, Suppl 1, p.
S59\u2013S66, 2000.
65. Phillipson BE, Rothrock DW, Connor WE, Harris WS. Reduction of plasma lipids,
lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceri-
demia. N Engl J Med, v. 312, p. 1210\u20131216, 1985.
66. Friedberg CE, Janssen MJEM, Heine RJ, Grobbee DE. Fish oil and glycemic control
in diabetes: a meta-analysis. Diabetes Care, v. 21, p. 494\u2013500, 1998.
67. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson J-L, Garg A et al. Evidence-
based nutrition principles and recommendations for the treatment and prevention
of diabetes and related complications (Technical Review). Diabetes Care, v. 25, p.
S136\u2013S138, 2002.
68. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J et al. A low-
carbohydrate as compared with a low fat diet in severe obesity. N Engl J Med, v.
48, p. 2074\u20132081, 2003.
69. Brehm BJ, Seeley RJ, Daniels SR, D\u2019Alessio DA. A randomized trial comparing a
very low carbohydrate diet and a calorie-restricted low fat diet on body weight and
cardiovascular risk factors in healthy women. J Clin Endocrinol Metab, v. 88, p.
1617\u20131623, 2003.
70. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS et al. A ran-
domized trial of a low-carbohydrate diet for obesity. N Engl J Med, v. 348, p.
2082\u20132090, 2003.
71. De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I et al. Mediter-
ranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart di-
sease. Lancet, v. 343, p. 1454\u20131459, 1994.
72. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean
diet, traditional risk factors, and the rate of cardiovascular complications after
myocardial infarction. Final Report of the Lyon Diet Heart Study. Circulation, v. 99,
p. 779\u2013785, 1999.
73. Balady GJ, Berra KA, Golding LA, Gordon NF, Mahler DA, Myers JN et al. Ameri-
can College of Sports Medicine. American College of Sports Medicine\u2019s guidelines
for exercise testing and prescription. 6th ed. Baltimore: Lippincott Williams &
Wilkins; 2000.
74. Di Matteo MR, Giordani PJ, Croghan TW. Patient adherence and medical treat-
ment outcomes \u2013 A meta-analysis. Medical Care, v. 40, p. 794\u2013811, 2002.
75. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pres-
sure-lowering medication in ambulatory care? Systematic review of randomized
controlled trials. Arch Intern Med, v. 164, p. 722\u2013732, 2004.
76. World Health Organization. Adherence to long-term therapies. Evidence for action
Genebra: 2003.
77. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihi-
pertensive therapies used as first-line agents. A systematic review and meta-analy-
sis. JAMA, v. 277, p. 739\u2013745, 1977.
78. Wright JM, Lee C-H, Chamber GK. Systematic review of antihypertensive thera-
pies: does the evidence assist in choosing a first-line drug. Can Med Ass J, v. 161,
p. 25\u201332, 1999.
79. SHEP\u2013Cooperative Research Group. Prevention of stroke by antihypertensive drug
treatment in older persons with isolated systolic hypertension: final results of the Sys-
tolic Hypertension in the Elderly Program (SHEP). JAMA, v. 265, p. 3255\u20133264, 1991.
80. Medical Research Council Working Party. MRC trial of treatment of hypertension:
principal results. BMJ, v. 291, p. 97\u2013104, 1985.
81. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reduc-
ing risk of macrovascular and microvascular complications in type 2 diabetes.
(UKPDS 39). BMJ, v. 317, p. 713\u2013720, 1998.
82. Blood Pressure Lowering Trialist\u2019s Collaboration. Effects of ACE inhibitors, calcium
antagonists and other blood-pressure-lowering drugs: results of prospectively de-
signed overviews of randomized trials. Lancet, v. 356, p. 1955\u20131964, 2000.
83. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin converting enzy-
me inhibition compared with conventional therapy on cardiovascular morbidity
and mortality on hypertension: the Captopril Prevention Project (CAPPP) randomi-
zed trial. Lancet, v. 353, p. 611\u2013616, 1999.
84. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an
angiotensin converting enzyme inhibitor, ramipril on cardiovascular events in high-
risk patients. N Engl J Med, v. 342, p. 145\u2013153, 2000.
85. PROGRESS Collaborative Group. Randomized Trial of a perindopril-based-blood
pressure-lowering regimen among 6,105 individuals with previous stroke or tran-
sient ischemic attack. Lancet, v. 35, p. 1033\u20131041, 2001.
86. Hansson